NASDAQ:AURA

Aura Biosciences - AURA Stock Forecast, Price & News

$9.28

+0.40 (+4.50%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $8.89
▼
$9.40
50-Day Range: $8.88
▼
$12.11
52-Week Range: $8.63
▼
$24.83

Volume: 126,085 shs
Average Volume: 178,807 shs
Market Capitalization: $350.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Institutional Ownership

Aura Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 169.4% Upside
$25.00 Price Target
Short Interest: Bearish
4.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$3,960 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.17) to ($2.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

821st out of 996 stocks

Biological Products, Except Diagnostic Industry

140th out of 165 stocks

3.5

Analyst's Opinion

Consensus Rating
Aura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.00, Aura Biosciences has a forecasted upside of 169.4% from its current price of $9.28.
Amount of Analyst Coverage
Aura Biosciences has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.83% of the float of Aura Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Aura Biosciences has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Aura Biosciences has recently increased by 30.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aura Biosciences does not currently pay a dividend.
Dividend Growth
Aura Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AURA.

0.6

News and Social Media Coverage

News Sentiment
Aura Biosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aura Biosciences this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aura Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,960.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Aura Biosciences is held by insiders.
Percentage Held by Institutions
55.63% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aura Biosciences are expected to decrease in the coming year, from ($2.17) to ($2.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aura Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aura Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aura Biosciences has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AURA Stock News Headlines

March 20, 2023 | benzinga.com

Aura Biosciences Stock (NASDAQ:AURA), Dividends

March 20, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Top Glove Bhd (TPGVF), Aura Biosciences Inc (AURA)

April 2, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.

March 15, 2023 | finance.yahoo.com

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

March 14, 2023 | marketwatch.com

Coating Buffer Market Size, Share & Trends Analysis Report By Product, By Application, By Region, And Segment Forecasts, 2023 - 2030

February 24, 2023 | finance.yahoo.com

Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate

February 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Aura Biosciences Inc (AURA) and Amedisys (AMED)

February 16, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)

April 2, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.

February 16, 2023 | msn.com

Aura rises after updating Phase 2 data for eye cancer therapy

February 16, 2023 | finance.yahoo.com

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

February 10, 2023 | finance.yahoo.com

Why Shares of Aura Biosciences Jumped This Week

January 21, 2023 | nasdaq.com

Chiesi Ventures, Inc. Cuts Stake in Aura Biosciences Inc (AURA)

December 24, 2022 | finance.yahoo.com

Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses

December 1, 2022 | marketwatch.com

Aura Biosciences Shares Drop 19% After Public Offering Prices

December 1, 2022 | finance.yahoo.com

Aura Biosciences Announces Pricing of Public Offering of Common Stock

November 30, 2022 | seekingalpha.com

Aura Biosciences announces stock offering, size not disclosed

November 24, 2022 | finance.yahoo.com

Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year

November 11, 2022 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Paragon 28 (FNA) and Aura Biosciences Inc (AURA)

November 10, 2022 | finance.yahoo.com

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

November 10, 2022 | finance.yahoo.com

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

October 6, 2022 | finance.yahoo.com

Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation

October 4, 2022 | finance.yahoo.com

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

October 3, 2022 | seekingalpha.com

Aura sheds 16% after Phase 2 data for eye cancer therapy

October 3, 2022 | finance.yahoo.com

Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug

October 3, 2022 | finance.yahoo.com

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

October 3, 2022 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Aura Biosciences Inc (AURA)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AURA Company Calendar

Last Earnings: 3/15/2023
Today: 4/01/2023
Next Earnings (Estimated): 5/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AURA
CUSIP: N/A
CIK: 1501796
Web: www.aurabiosciences.com
Phone: 617-500-8864
Fax: N/A
Employees: 52
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +169.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.25%
Return on Assets: -36.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.81
Quick Ratio: 18.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.67 per share
Price / Book: 1.39

Miscellaneous

Outstanding Shares: 37,800,000
Free Float: 35,910,000
Market Cap: $350.78 million
Optionable: Not Optionable
Beta: 0.12

Key Executives

Dr. Elisabet de los Pinos Ph.D. (Age 49)
Founder, CEO, Pres & Director
Comp: $676.62k

Ms. Julie B. Feder (Age 53)
CFO, Sec. & Treasurer
Comp: $505.45k

Dr. Cadmus Collins Rich CPE (Age 58)
M.B.A., M.D., MBA, Chief Medical Officer and Head of R&D
Comp: $564.22k

Dr. Mark A. De Rosch Ph.D. (Age 59)
Chief Operating Officer

Mr. Paulo Carvalho
VP of Technical Operations

Mr. Joseph Lyons
VP of HR

Ms. Michele Keough M.B.A.
Sr. VP of Project Management and Device Supply Chain

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AURA Stock - Frequently Asked Questions

Should I buy or sell Aura Biosciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares.
View AURA analyst ratings or view top-rated stocks.
What is Aura Biosciences' stock price forecast for 2023?: 1 brokerages have issued 12-month price objectives for Aura Biosciences' shares. Their AURA share price forecasts range from $25.00 to $25.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 169.4% from the stock's current price.
View analysts price targets for AURA or view top-rated stocks among Wall Street analysts.
How have AURA shares performed in 2023?: Aura Biosciences' stock was trading at $10.50 at the beginning of 2023. Since then, AURA shares have decreased by 11.6% and is now trading at $9.28.
View the best growth stocks for 2023 here.
Are investors shorting Aura Biosciences?: Aura Biosciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,250,000 shares, an increase of 30.2% from the February 28th total of 960,000 shares. Based on an average daily trading volume, of 115,300 shares, the days-to-cover ratio is currently 10.8 days. Approximately 4.8% of the shares of the company are short sold.
View Aura Biosciences' Short Interest.
When is Aura Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our AURA earnings forecast.
How were Aura Biosciences' earnings last quarter?: Aura Biosciences, Inc. (NASDAQ:AURA) announced its earnings results on Wednesday, March, 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.06.

What ETFs hold Aura Biosciences' stock?: ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include AltShares Event-Driven ET (EVNT).ALPS Medical Breakthroughs ETF (SBIO).
When did Aura Biosciences IPO?: (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share.
What is Aura Biosciences' stock symbol?: Aura Biosciences trades on the NASDAQ under the ticker symbol "AURA."
How do I buy shares of Aura Biosciences?: Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aura Biosciences' stock price today?: One share of AURA stock can currently be purchased for approximately $9.28.
How much money does Aura Biosciences make?: Aura Biosciences (NASDAQ:AURA) has a market capitalization of $350.78 million. The company earns $-58,760,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis.
How can I contact Aura Biosciences?: The official website for the company is www.aurabiosciences.com. The company can be reached via phone at 617-500-8864 or via email at aura@argotpartners.com.

This page (NASDAQ:AURA) was last updated on 4/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aura Biosciences - AURA Stock Forecast, Price & News

Aura Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aura Biosciences (NASDAQ:AURA) Stock

AURA Stock News Headlines

AURA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AURA Stock - Frequently Asked Questions

Overall MarketRank^™